Compare DexCom, Inc. (DXCM) vs Guardant Health Inc. Common Stock (GH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Guardant Health Inc. Common Stock — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Guardant Health Inc. Common Stock trades at $165.58 (market cap $22.22B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 1,589,453). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Guardant Health Inc. Common Stock for 0 Days on average.
| DXCM | GH | |
|---|---|---|
Market Cap | $31.86B | $22.22B |
Volume | 3,607,070 | 1,589,453 |
Sector | Health | Health |
52-Week High | $92.34 | $187.22 |
52-Week Low | $54.84 | $61.73 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.32B | $22.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →
